Jihong Han Selected Research

asparaginyl- isoleucyl- prolyl- norvalyl- leucyl- tyrosyl- seryl- phenylalanyl- alanyl- serinamide

12/2020	Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
1/2017	Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jihong Han Research Topics

Disease

34	Atherosclerosis 01/2022 - 01/2008
20	Inflammation (Inflammations) 01/2022 - 04/2014
13	Neoplasms (Cancer) 12/2022 - 07/2010
8	Fatty Liver 01/2022 - 01/2018
8	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 06/2002
6	Coronary Disease (Coronary Heart Disease) 01/2022 - 11/2004
5	Thrombosis (Thrombus) 01/2022 - 09/2003
5	Vascular Calcification 01/2022 - 10/2018
4	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022 - 01/2018
4	Insulin Resistance 01/2021 - 01/2019
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2014
4	Breast Neoplasms (Breast Cancer) 12/2018 - 05/2015
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 01/2018
3	Sepsis (Septicemia) 12/2021 - 01/2018
3	Fibrosis (Cirrhosis) 03/2021 - 11/2019
3	Heart Failure 12/2020 - 01/2016
3	Non-alcoholic Fatty Liver Disease 12/2020 - 02/2018
3	Vascular Diseases (Vascular Disease) 03/2020 - 01/2019
3	Dyslipidemias (Dyslipidemia) 01/2020 - 04/2015
3	Hypertriglyceridemia 01/2020 - 04/2015
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2020
2	Ischemic Stroke 01/2022 - 01/2019
2	Stroke (Strokes) 01/2022 - 01/2016
2	Obesity 01/2022 - 01/2020
2	Virus Diseases (Viral Diseases) 11/2021 - 12/2018
2	Cardiotoxicity 06/2021 - 12/2020
2	Wounds and Injuries (Trauma) 06/2021 - 01/2017
2	Cholestasis 03/2021 - 01/2020
2	Atrophy 03/2021 - 01/2021
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2019
2	Liver Cirrhosis (Hepatic Cirrhosis) 12/2020 - 11/2019
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2020 - 01/2020
2	Body Weight (Weight, Body) 12/2020 - 06/2015
2	Hypercholesterolemia 11/2020 - 01/2017
2	Necrosis 01/2020 - 11/2019
2	Neoplasm Metastasis (Metastasis) 12/2018 - 01/2016
2	Vascular Remodeling 01/2018 - 01/2017
2	Diabetic Retinopathy (Retinopathy, Diabetic) 06/2015 - 01/2015

Drug/Important Bio-Agent (IBA)

16	Apolipoproteins E (ApoE)IBA 01/2022 - 04/2015
12	LipidsIBA 01/2022 - 09/2003
10	LigandsIBA 01/2022 - 06/2009
9	Liver X ReceptorsIBA 01/2021 - 12/2012
9	Capsules (Microcapsules)IBA 01/2021 - 01/2015
9	CholesterolIBA 01/2019 - 06/2002
7	T0901317IBA 01/2021 - 04/2014
7	naoxintongIBA 01/2021 - 01/2015
6	Glucose (Dextrose)FDA LinkGeneric 06/2021 - 06/2015
5	U 0126 (UO 126)IBA 01/2022 - 02/2015
5	CollagenIBA 03/2021 - 05/2015
5	danhongIBA 01/2018 - 05/2014
4	ApolipoproteinsIBA 01/2022 - 05/2014
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 03/2020
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2007
4	Transcription Factors (Transcription Factor)IBA 06/2021 - 12/2012
4	LDL Receptors (LDL Receptor)IBA 01/2021 - 01/2008
4	Rosiglitazone (Avandia)FDA Link 01/2021 - 11/2019
4	LongShengZhiIBA 03/2020 - 01/2019
4	oxidized low density lipoproteinIBA 01/2020 - 12/2012
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2018 - 11/2004
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022 - 01/2016
3	CarrageenanIBA 01/2022 - 01/2018
3	Small Interfering RNA (siRNA)IBA 01/2022 - 05/2016
3	Pharmaceutical PreparationsIBA 11/2021 - 01/2020
3	Monoamine Oxidase (MAO)IBA 11/2021 - 01/2019
3	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2021 - 03/2020
3	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2021 - 11/2019
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2021 - 11/2019
3	Collagen Type I (Type I Collagen)IBA 03/2021 - 11/2019
3	InterferonsIBA 01/2021 - 02/2015
3	CytokinesIBA 01/2021 - 11/2011
3	Tamoxifen FDA LinkGeneric 12/2018 - 05/2015
3	Teniposide (VM 26)FDA Link 12/2018 - 06/2013
3	trioctyl phosphine oxide (TOPO)IBA 12/2018 - 06/2013
3	buchang naoxintongIBA 01/2017 - 01/2015
3	pitavastatin (itavastatin)FDA Link 08/2015 - 09/2003
3	Fatty Acid-Binding ProteinsIBA 08/2015 - 06/2012
2	Therapeutic UsesIBA 01/2022 - 01/2019
2	Biological ProductsIBA 12/2021 - 01/2021
2	AntioxidantsIBA 06/2021 - 09/2015
2	EnzymesIBA 06/2021 - 03/2020
2	Toll-Like Receptor 4IBA 03/2021 - 01/2021
2	Glutathione PeroxidaseIBA 03/2021 - 01/2020
2	CatalaseIBA 03/2021 - 03/2020
2	PPAR gammaIBA 01/2021 - 06/2009
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2019
2	Urethane (Ethyl Carbamate)IBA 01/2021 - 01/2016
2	HydrogelsIBA 01/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2021 - 12/2020
2	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2020
2	AdiponectinIBA 12/2020 - 01/2017
2	asparaginyl- isoleucyl- prolyl- norvalyl- leucyl- tyrosyl- seryl- phenylalanyl- alanyl- serinamideIBA 12/2020 - 01/2017
2	Adenosine Monophosphate (AMP)IBA 12/2020 - 02/2018
2	Oxidoreductases (Dehydrogenase)IBA 03/2020 - 09/2003
2	Carthamus tinctorius Honghua extractIBA 01/2020 - 05/2014
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 12/2018 - 06/2013
2	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2016 - 01/2016

Therapy/Procedure

8	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 01/2019
8	Therapeutics 01/2021 - 07/2010
2	Oral Administration 01/2021 - 01/2021